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Edited by Vladimir SkulachevAbstract The AMP-activated protein kinase (AMPK) cascade
is a sensor of cellular energy charge that promotes catabolic and
inhibits anabolic pathways. However, the role of AMPK in
adipocytes is poorly understood. We show that transgenic
expression of mitochondrial uncoupling protein 1 in white fat,
which induces obesity resistance in mice, is associated with
depression of cellular energy charge, activation of AMPK,
downregulation of adipogenic genes, and increase in lipid
oxidation. Activation of AMPK may explain the complex
metabolic changes in adipose tissue of these animals and our
results support a role for adipocyte AMPK in the regulation of
storage of body fat.
 2004 Federation of European Biochemical Societies.
Published by Elsevier B.V. All rights reserved.
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It is becoming evident that metabolism of adipose tissue is
important for the control of body fat content [1,2] and that
intracellular energy charge is involved in the control of lipid
metabolism in adipocytes. In vitro studies demonstrated that a
decrease of mitochondrial ATP production resulted in the in-
hibition of both fatty acid (FA) synthesis [3] and the lipolytic
action of catecholamines [4]. In turn, lipolytic hormones de-
creased ATP levels in adipocytes [5,6]. The intracellular energy
charge is also low [7,8] in transgenic mice [9] rendered resistant
to obesity by ectopic expression of mitochondrial uncoupling
protein 1 (UCP1) in white fat (aP2-Ucp1 mice). These animals* Corresponding author. Fax: +420-241-062-599.
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doi:10.1016/j.febslet.2004.06.002exhibited a reduction of FA synthesis [10] and the lipolytic
action of catecholamines [7], as well as increases in mitochon-
drial biogenesis [11] and endogenous oxygen consumption [12]
in white adipose tissue. At that time, a unifying explanation for
all of these metabolic changes was not apparent.
The AMP-activated protein kinase (AMPK) is a sensor of
cellular energy charge that, once activated by an increase in the
cellular AMP/ATP ratio, acts as a metabolic master switch
[13,14]. Its known eﬀects include: (a) inhibition of FA synthesis
and lipolysis in adipocytes due to phosphorylation of acetyl-
CoA carboxylase-1 (ACC-1) and hormone-sensitive lipase [15–
17]; (b) stimulation of glucose uptake into adipocytes [18] and
myocytes [19]; (c) activation of FA oxidation in muscle due to
phosphorylation of ACC-2 [19,20]; (d) induction of mitochon-
drial biogenesis possibly through activation of nuclear respi-
ratory factor-1 [21]; and (e) downregulation of lipogenic genes
in liver [22], as well as in 3T3-L1 adipocytes, in the latter case by
downregulating peroxisome proliferator-activated receptor c
(PPARc; [23]). The role of AMPK in adipose tissue remains
relatively unexplored, although recent studies indicate the in-
volvement of AMPK in the eﬀects of physical exercise [24],
adiponectin [18], thiazolidinediones [25], and leptin [26,27].
The aim of this study was to verify whether changes in the
energy charge of adipocytes in vivo, due to respiratory uncou-
pling in aP2-Ucp1 mice, could activate AMPK in adipocytes,
and to clarify further the role of AMPK in white adipose tissue.2. Materials and methods
2.1. Animals
Male C57BL/6J control mice and their transgenic littermates, hemi-
zygous for the aP2-Ucp1 transgene [9,12,28], were kept in a controlled
environment (20 C; 12 h light/dark cycle) with free access to water and
standard chow diet. At 6 months of age, animals were sacriﬁced by
cervical dislocation under diethylether anesthesia. Epididymal and
subcutaneous dorsolumbar white fat depots [12] were dissected, ﬂash
frozen and stored in liquid nitrogen for biochemical and RNA analysis.
2.2. RNA analysis
Gene expression was analyzed by reverse transcription followed by
the real time quantitative PCR (LightCycler Instrument, Roche, Ger-
many) with primers speciﬁc for PPARc, adipocyte lipid binding protein
2 (aP2) and b-actin (Table 1). Levels of b-actin were used to correct for
inter-sample variations. Detailed protocol was described before [7].blished by Elsevier B.V. All rights reserved.
Table 1
Sequences of PCR primers
Gene Sense primer (50–30) Antisense primer (50–30) GenBank Accession No. for cDNA
PPARca GGCGAGGGCGATCTTGACAGG GGGCTTCCGCAGGTTTTTGAGG U09138
b-Actin GAACCCTAAGGCCAACCGTGAAAAGAT ACCGCTCGTTGCCAATAGTGATG XO3765
aP2 AACACCGAGATTTCCTTCAA AGTCACGCCTTTCATAACACA M13385
aBoth isoforms c1 and c2 are ampliﬁed.
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Flash-frozen tissues dissected immediately after sacriﬁce were stored
in liquid nitrogen. Tissues were homogenized in 6% (w/v) perchloric
acid. After centrifugation, supernatants were neutralized and adenine
nucleotides determined using HPLC [7].
2.4. Activity of a1 isoform of AMPK
AMPK was immunoprecipitated from tissue extracts prepared by
homogenization in buﬀer A and the activity was assayed using a
peptide substrate [29]. Protein concentration was estimated using bi-
cinchoninic acid procedure and BSA as a standard [7]. AMPK activity
is expressed in Units (nmol phosphate/min) per mg of protein in the
adipocyte extract used for immunoprecipitation.
2.5. Oxidation of FA
Oxidation of oleic acid was measured using a modiﬁed protocol of
Wang et al. [30]. Adipose tissue (35 mg) sliced up into 5–10 fragments
was pre-labeled with 40 lCi/mL [9,10(n)-3H]oleic acid in 300 ll of 2%
FA-free BSA-KRB buﬀer containing 5 mM glucose for 75 min at 37 C
and under 5% CO2 (gentle shaking). Fragments were washed three
times and re-suspended in 500 ll of the buﬀer and incubated for ad-
ditional 4 h at 37 C. Oxidation was assessed by measuring the amount
of 3H2O released into the medium. The content of free FA in adipose
tissue fragments was measured in 5% homogenate (w/v in H2O) using a
NEFA C kit from Wako Chemicals (Richmond, VA) and results were
calculated according to a published formula [30].
2.6. Quantiﬁcation of AMPK and ACC
The total content of the a1 catalytic subunit of AMPK (a1 AMPK)
and the phosphorylated form of AMPK (pAMPK) was determined in
tissue lysates by Western blotting [29,31] using antibodies against total
a1AMPK [31] and phosphospeciﬁc antibodies against Thr-172 [32]. For
the quantiﬁcation of total ACC and the phosphorylated form of ACC
(pACC), tissue lysates (10 lg protein) were subjected to SDS–PAGE
using pre-cast 3–8% Tris-acetate gels (Invitrogen). Protein was trans-
ferred to nitrocellulose membranes (BioRad, Hercules, CA) and the
membranes incubated in Odyssey Blocking buﬀer (Li-Cor Biosciences,
Lincoln, NE). Phosphospeciﬁc sheep antibodies against the Ser-221 site
on ACC-2 [29], that also recognize the homologous site (Ser-79) on
ACC-1 (1.46 lg/ml in blocking buﬀer containing 0.2% Tween-20), were
used to quantify pACC (incubation for 1 h). The membranes were
washed 6 5 min with TBS (10 mM Tris–HCl, pH 7.4, 0.5 M NaCl)
containing Tween-20 (0.2%) and immersed in blocking buﬀer contain-
ing 0.2%Tween-20 and 1 lg/ml anti-sheep IgG conjugated to IR dye 680
(Molecular Probes, Leiden, The Netherlands) and 1 lg/ml streptavidin
conjugated to IR Dye 800 (Rockland Inc., Philadelphia, PA) and left
shaking for 1 h, protected from light. The membranes were then washed
6 5 min using TBS-Tween (0.2%) and 1 5 min in PBS and scanned
using the Odyssey IR Imager (Li-Cor Biosciences). The results were
quantiﬁed using Odyssey software. A linear response was obtained
between 0.3 and 20 lg lysate protein analyzed (not shown).
2.7. Statistics
Statistical signiﬁcance was evaluated using unpaired t-tests. Diﬀer-
ences were judged to be signiﬁcant at P < 0:05.Fig. 1. AMP/ATP ratio and AMPK activity in adipose tissue. (A)
Concentrations of ATP and AMP were estimated by HPLC in tissue
extracts (n ¼ 15). (B) Activity of a1 AMPK (in units; n ¼ 6). Values
are means S.E. Asterisks indicate statistically signiﬁcant diﬀerences
between genotypes.3. Results
3.1. Increased cellular AMP/ATP ratio
We observed previously [7] that in white fat of the aP2-Ucp1
mice ATP content was lower and ADP/ATP ratio was higher
than in control mice. These diﬀerences were more pronouncedin subcutaneous than in epididymal fat, in accordance with a
higher content of transgenic UCP1 in the former fat depot [7].
Due to the adenylate kinase reaction [13], we expected that the
AMP/ATP ratio should be also aﬀected by ectopic expression
of UCP1 in white fat. It was observed that the AMP/ATP ratio
in both fat depots of transgenic animals was higher than in
control mice (Fig. 1A). No statistically signiﬁcant diﬀerences
between the two genotypes could be detected at the level of
tissue contents of individual nucleotides (not shown).
3.2. Enhancement of AMPK activity
The increase of the AMP/ATP ratio produced by ectopic
expression of UCP1 in white fat suggested that AMPK activity
in adipose tissue would be also aﬀected. Indeed, the presence of
transgenic UCP1 resulted in a signiﬁcant, 2-fold increase in the
activity of the a1 isoform (a1 AMPK) in subcutaneous fat
(Fig. 1B). The activity also tended to be higher in the epidid-
ymal fat, although this was not statistically signiﬁcant
(Fig. 1B). The activity of the a2 isoform was negligible in
adipose tissue (not shown). Quantiﬁcation of the expression of
a1 AMPK and phosphorylation of Thr-172 using Western
blots (Fig. 2A) indicated a signiﬁcantly higher content of the
a1 subunit in transgenic than in control mice in both epidid-
ymal and subcutaneous fat (Fig. 2B) and, after correction for
a1 content, a signiﬁcant increase in a1 AMPK phosphoryla-
Table 2
Downregulation of PPARc and aP2 gene expression in adipose tissue
of transgenic mice
Sample mRNA level (relative units %)
PPARc aP2
Subcutaneous fat
+/+ 100.0 15.6 100 17.6
tg/+ 22.9 6.2* 32.8 6.4*
Epididymal fat
+/+ 100.0 11.6 100 12.5
tg/+ 68.1 26.1 80.7 12.6
Transcripts were quantiﬁed in adipose tissue of control (+/+) and
transgenic mice (tg/+). Data are meansS.E. (n ¼ 5 to 6). Asterisks
indicate statistically signiﬁcant diﬀerences between genotypes. Results
were veriﬁed using Northern blot analysis (not shown).
Fig. 3. Oxidation of oleate in adipose tissue. Values are meansS.E.
(n ¼ 6). Asterisk indicates statistically signiﬁcant diﬀerences between
genotypes.
Fig. 2. Content and phosphorylation of AMPK in adipose tissue. (A)
Total a1 AMPK and phosphorylated form of a1 AMPK (pAMPK)
were quantiﬁed using Western blots, as illustrated for the analysis in
subcutaneous fat. (B) Total content of a1 AMPK. (C) Phosphorylation
of AMPK. Values are means S.E. (n ¼ 6). Asterisks indicate statis-
tically signiﬁcant diﬀerences between genotypes.
O. Matejkova et al. / FEBS Letters 569 (2004) 245–248 247tion in both fat depots due to the transgenic modiﬁcation
(Fig. 2C). Quantiﬁcation of total ACC and pACC content in
adipose tissue lysates (see Section 2) also showed a modest but
signiﬁcant increase of the pACC/ACC ratio (1.3-fold;
P < 0:05; n ¼ 6) in subcutaneous fat due to the transgenic
modiﬁcation. Increased phosphorylation of both a1 AMPK
and ACC in the transgenic mice further supports the activation
of AMPK by the ectopic UCP1 in white fat.
3.3. Decreased expression of PPARc and aP2 genes
In order to further characterize the complex changes in lipid
metabolism in the transgenic mice, expression of the PPARc
gene was analyzed. PPARc plays a crucial regulatory role in
adipogenesis and its expression is inhibited by AMPK activa-
tion during diﬀerentiation of 3T3-L1 adipocytes in culture [23].
A signiﬁcant diminution of PPARc mRNA level was found in
subcutaneous but not in epididymal fat of aP2-Ucp1 mice
(Table 2). Moreover, the expression of a PPARc target gene,
i.e., aP2, was also downregulated in subcutaneous fat (Table 2).
3.4. Enhancement of FA oxidation
Previous experiments showed a higher rate of oxidation of
endogenous substrates in white fat of transgenic compared
with control mice [12]. Measurement of oleate oxidation in
adipose tissue fragments (Fig. 3) revealed a similar rate of
oxidation in the subcutaneous and epididymal fat of control
mice. However, the presence of transgenic UCP1 resulted in a
signiﬁcant, 2.7-fold increase in the oleate oxidation in subcu-
taneous fat, but not epididymal fat.4. Discussion
Our results demonstrate that persistent depression of energy
charge in adipocytes of the transgenic mice results in both an
increase of a1 AMPK expression, and an increase in its
phosphorylation and activity. Increased expression of a1 has
been observed in other tissues in response to treatments that
would be expected to persistently activate AMPK, e.g., during
pressure overload hypertrophy in rat heart [33], or endurance
training in human skeletal muscle [34]. The diﬀerential eﬀect of
the transgene on AMPK activity in the subcutaneous versus
the epididymal fat depots was in accordance with the 2- to 3-
fold higher expression of the transgene in the former, detected
at both the mRNA and protein levels [10,11], and also with the
preferential eﬀect of the transgene on lipogenesis [10], lipolysis
[7], and FA oxidation (this report, Fig. 3) in the subcutaneous
fat. The strong induction of FA oxidation, the increase in
mitochondrial content [11], and the depression of lipogenesis
[10] in subcutaneous fat of the transgenic mice are consistent
with the known eﬀects of AMPK in white fat [15,16] and other
tissues [13,14,20,21] and explain the preferential reduction of
subcutaneous fat in the transgenic mice [9,28]. Moreover, the
strong downregulation of PPARc and aP2 genes in the sub-
cutaneous fat of the transgenic mice, most probably due to the
activation of AMPK [23], may suppress the adipogenic po-
tential of the tissue. Thus, activation of AMPK in white fat of
aP2-Ucp1 mice, by depression of intracellular energy charge,
helps to explain the complexity of the changes in adipose tissue
metabolism and obesity resistance in this transgenic model.
248 O. Matejkova et al. / FEBS Letters 569 (2004) 245–248Besides the eﬀect of transgenic UCP1 on adipose tissue,
several other studies support a link between energy charge and
metabolism in adipocytes, and the involvement of AMPK: (a)
hyperleptinemia [26] and bezaﬁbrate treatment [35] deplete
body fat in rats, whereas expression of UCP1 and UCP2 in
white adipose tissue is up-regulated, FA oxidation is increased,
and expression of lipogenic genes is profoundly suppressed; (b)
in isolated adipocytes leptin inhibits lipid synthesis while
up-regulating UCP2 [36]; (c) antidiabetic drugs such as thia-
zolidinediones stimulate AMPK in adipose tissue [25], while
inducing glycerol kinases [37] and phosphoenolpyruvate
carboxykinase [38], leading presumably to futile cycling of FA
re-esteriﬁcation in adipocytes. Thiazolidinediones also stimu-
late AMPK in muscle cells while increasing the intracellular
AMP/ATP ratio [39]. In fact, the induction of UCPs by leptin
in adipose tissue, leading to a drop in the intracellular energy
charge, may partly explain the activation of AMPK in adipose
tissue under these conditions [27].
AMPK appears to represent a switch that converts adipo-
cytes to lipid burning cells while suppressing in situ lipogenesis.
This mechanism, which reduces the fat content of adipocytes,
exists not only in aP2-Ucp1 mice, but also under other cir-
cumstances such as hyperleptinemia [27]. Interestingly, FA
oxidation and synthesis in adipose tissue are also reciprocally
regulated during fasting [30]. Finally, the control of adipose
tissue metabolism by intracellular energy charge and AMPK
may represent a basic biological mechanism that contributes to
the regional diﬀerences in the metabolic properties of adipose
tissue depots. This mechanism could be aﬀected by physio-
logical stimuli, as well as by pharmacological agents, and it
represents a promising target for the development of strategies
for the treatment of both obesity and insulin resistance.
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